Abstract: An implantable drug delivery system includes a middle ear section with a proximal end fixed to a tympanic membrane of a patient, and a distal end that penetrates through a fluid-tight sealed opening into the inner ear. An inner ear section has a proximal end that is connected to the distal end of the middle ear guide member at the sealed opening, and a closed distal end terminating the inner ear holding member some predetermined distance within the cochlea. A hollow interior of the inner ear section is configured for containing a replaceable pharmaceutical agent, and an outer surface is configured to release the pharmaceutical agent from the hollow interior into the inner ear of the patient. The middle ear section and the inner ear section are configured to cooperate for replacing the pharmaceutical agent through the proximal end of the middle ear section to the inner ear section.

Abstract: An implantable drug delivery system includes a middle ear section with a proximal end fixed to a tympanic membrane of a patient, and a distal end that penetrates through a fluid-tight sealed opening into the inner ear. An inner ear section has a proximal end that is connected to the distal end of the middle ear guide member at the sealed opening, and a closed distal end terminating the inner ear holding member some predetermined distance within the cochlea. A hollow interior of the inner ear section is configured for containing a replaceable pharmaceutical agent, and an outer surface is configured to release the pharmaceutical agent from the hollow interior into the inner ear of the patient. The middle ear section and the inner ear section are configured to cooperate for replacing the pharmaceutical agent through the proximal end of the middle ear section to the inner ear section.

Abstract: The invention relates to compounds of general formula 1 to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts and/or solvates which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as inductors of apoptosis in the case of non-solid malignant tumors of the hematopoietic system, in particular in the case of leukemias and lymphomas, more particularly in the case of leukemic B lymphocytes.

Abstract: An implantable drug delivery accessory is described. A middle ear guide member has a hollow interior enclosed by a non-permeable outer surface. A proximal end of the middle ear guide member is fixed to the tympanic membrane of an implanted patient. A distal end of the middle ear guide member penetrates through a fluid-tight sealed opening into the inner ear. An inner ear holding member has a proximal end connected to the distal end of the middle ear guide member at the sealed opening and a closed distal end terminating the inner ear holding member some predetermined distance within the cochlea. A hollow interior of the inner ear holding member contains a replaceable drug delivery member which stores a therapeutic drug. A semi-permeable outer surface of the inner ear holding member is connected to a cochlear implant electrode and adapted to release therapeutic drug from the hollow interior into adjacent tissue.

Abstract: The invention relates to compounds of general formula 1 to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts and/or solvates which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as inductors of apoptosis in the case of non-solid malignant tumors of the hematopoietic system, in particular in the case of leukemias and lymphomas, more particularly in the case of leukemic B lymphocytes.